Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

9.370 +0.190 (+2.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,428,200
Open 9.150
Bid (Size) 9.250 (1)
Ask (Size) 9.370 (9)
Prev. Close 9.180
Today's Range 9.100 - 9.400
52wk Range 8.740 - 12.40
Shares Outstanding 1,212,301,241
Dividend Yield 5.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric
Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value. 
Via Talk Markets
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside. 
Via InvestorPlace

Performance

YTD
-17.66%
-17.66%
1 Month
+4.93%
+4.93%
3 Month
-11.77%
-11.77%
6 Month
+0.43%
+0.43%
1 Year
-16.11%
-16.11%

More News

Read More
7 Low P/E Stocks Poised to Rebound
Via InvestorPlace
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Recap: Viatris Q3 Earnings
Via Benzinga
2 Top Value Stocks to Buy in October
Via The Motley Fool
3 Large-Cap Stocks to Buy Trading Below Book Value
Via InvestorPlace
Topics Stocks
Exposures US Equities
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Via The Motley Fool
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
Via The Motley Fool
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
Via The Motley Fool
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Via Benzinga
Earnings Scheduled For November 7, 2023
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Via Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion
Via Investor's Business Daily
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
Via Benzinga
Could Viatris Stock Help You Become a Millionaire?
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Via Benzinga
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc.
Via SBWire
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
Via Benzinga
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.